Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 172
Filter
2.
Eur J Neurol ; 16(6): 771-4, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19236470

ABSTRACT

BACKGROUND AND PURPOSE: Amyotrophic lateral sclerosis (ALS) is classically assumed to be a neurodegenerative disorder. Inflammation has been observed in CNS tissue in ALS patients. We investigated the expression and prognostic relevance of proinflammatory chemokines in ALS. METHODS: We analyzed nine chemokines, eotaxin, eotaxin-3, IL-8, IP-10, MCP-1, MCP-4, macrophage derived chemokine (MDC), macrophage inflammatory protein-1beta (MIP-1beta), and serum thymus and activation- regulated chemokine (TARC) in serum and cerebrospinal fluid (CSF) of 20 ALS- and 20 non-inflammatory neurological disease (NIND)-patients. RESULTS: MCP-1 and IL-8 levels in CSF in ALS were significantly higher than in NIND (1304 pg/ml vs. 1055 pg/ml, P = 0.013 and 22.7 pg/ml vs. 18.6 pg/ml, P = 0.035). The expression of MCP-1 and IL-8 were higher in CSF than in serum (P < 0.001). There was a trend towards higher MCP-1 CSF levels in ALS patients with shorter time between first symptoms and diagnosis (r = -0.407; P = 0.075). CONCLUSIONS: We confirmed previous findings of increased MCP-1 levels in CSF of ALS patients. Furthermore, increased levels of IL-8 in CSF suggest a stimulation of a proinflammatory cytokine cascade after microglia activation. We found a tendency for higher MCP-1 values in patients with a shorter diagnostic delay, who are known to have also a shorter survival. This may suggest an association of higher MCP-1 levels with rapidly progressing disease.


Subject(s)
Amyotrophic Lateral Sclerosis/diagnosis , Chemokines/analysis , Inflammation/diagnosis , Amyotrophic Lateral Sclerosis/blood , Amyotrophic Lateral Sclerosis/cerebrospinal fluid , Biomarkers/analysis , Biomarkers/blood , Biomarkers/cerebrospinal fluid , Chemokine CCL2/analysis , Chemokine CCL2/blood , Chemokine CCL2/cerebrospinal fluid , Chemokines/blood , Chemokines/cerebrospinal fluid , Disease Progression , Early Diagnosis , Gliosis/blood , Gliosis/cerebrospinal fluid , Gliosis/diagnosis , Humans , Inflammation/blood , Inflammation/cerebrospinal fluid , Interleukin-8/analysis , Interleukin-8/blood , Interleukin-8/cerebrospinal fluid , Microglia/immunology , Microglia/metabolism , Predictive Value of Tests , Prognosis , Sensitivity and Specificity , Time Factors , Up-Regulation/immunology
3.
J Neurol ; 255(1): 77-88, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18204807

ABSTRACT

Several hereditary conditions affecting cerebral, retinal and systemic microvessels have recently been described. They include CADASIL, CRV, and HERNS. We here report on a variant form of a hereditary systemic angiopathy (HSA) affecting two generations of a Caucasian family. Clinical symptoms of HSA appear in the mid-forties and are characterized by visual impairment, migraine-like headache, skin rash, epileptic seizures, progressive motor paresis and cognitive decline. Late symptoms include hepatic and renal failure. Retinal capillary microaneurysms and arteriolar tortuosity are associated with marked optic disc atrophy. Radiological hallmarks consist of multiple cerebral calcifications and tumor-like subcortical white matter lesions. Brain, peripheral nerve, muscle, kidney and colon biopsies have revealed a multi organ small vessel involvement with partly altered endothelium, perivascular inflammation and thrombotic microangiopathy. No curative therapeutic options are known for hereditary cerebral vasculopathies. The use of cyclophosphamide, azathioprine and methotrexate was of no benefit in our cases of HSA. Early diagnosis of hereditary systemic angiopathies is important in order to prevent patients from repetitive invasive diagnostic measures and to avoid the use of inappropriate and potentially harmful drugs.


Subject(s)
Cerebral Arterial Diseases/pathology , Kidney Diseases/pathology , Liver Diseases/pathology , Retinal Diseases/pathology , Vascular Diseases/pathology , Adult , Aged , Brain/blood supply , Brain/pathology , Brain/physiopathology , Calcinosis/pathology , Calcinosis/physiopathology , Cerebral Arterial Diseases/physiopathology , Cerebral Arteries/pathology , Cerebral Arteries/physiopathology , Disease Progression , Early Diagnosis , Female , Humans , Immunosuppressive Agents/therapeutic use , Kidney Diseases/physiopathology , Liver Diseases/physiopathology , Liver Failure/pathology , Liver Failure/physiopathology , Male , Microcirculation/pathology , Microcirculation/physiopathology , Middle Aged , Renal Insufficiency/pathology , Renal Insufficiency/physiopathology , Retinal Artery/pathology , Retinal Artery/physiopathology , Retinal Diseases/physiopathology , Syndrome , Treatment Outcome , Vascular Diseases/physiopathology , Vasculitis/pathology , Vasculitis/physiopathology , Viscera/blood supply , Viscera/pathology , Viscera/physiopathology
9.
AJNR Am J Neuroradiol ; 27(6): 1272-4, 2006.
Article in English | MEDLINE | ID: mdl-16775278

ABSTRACT

Palatal tremor (PT), also known as palatal myoclonus, is defined by short rhythmic contractions of the palatal musculature. Functional MR imaging (fMRI) revealed prominent bilateral neuronal activation in the putamen associated with essential palatal tremor (EPT) in a 41-year-old man. This implies a central role of the putamen in EPT, most likely as a consequence of diminished inhibition in an afferent pathway. Because fMRI primarily detects activations, dysfunctional areas remain obscure. The present functional study complements previous pathologic studies, which associated PT with lesions to dentate nucleus, red nucleus, and the inferior olive (Guillain-Mollaret triangle).


Subject(s)
Brain Mapping , Essential Tremor/physiopathology , Magnetic Resonance Imaging , Palatal Muscles/physiopathology , Putamen/physiopathology , Adult , Afferent Pathways , Humans , Male , Muscle Contraction , Neck Muscles/physiopathology
10.
Neurology ; 66(5): 742-4, 2006 Mar 14.
Article in English | MEDLINE | ID: mdl-16534115

ABSTRACT

Rituximab has been administered successfully in patients with polyneuropathy associated with antibodies to myelin-associated glycoprotein (anti-MAG). The authors present a follow-up study with high-dose rituximab. Increase of rituximab from 375 mg/m2 to a dose of 750 mg/m2 was well tolerated and led to clinical improvement in four of eight patients, along with improvement of nerve conduction velocities and a reduction of anti-MAG antibody titers.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Immunologic Factors/therapeutic use , Myelin-Associated Glycoprotein/immunology , Polyneuropathies/drug therapy , Polyneuropathies/immunology , Aged , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Murine-Derived , Antibody-Dependent Cell Cytotoxicity , B-Lymphocytes/immunology , Female , Follow-Up Studies , Humans , Immunoglobulin M/blood , Immunologic Factors/adverse effects , Male , Middle Aged , Rituximab , Time Factors
11.
Praxis (Bern 1994) ; 95(8): 263-8, 269-71, 2006 Feb 22.
Article in German | MEDLINE | ID: mdl-16523990

ABSTRACT

Although disease-specific treatment of amyotrophic lateral sclerosis is still unsatisfactory, a number of advances have been made in the symptomatic therapy of ALS patients within the last decade. Current data suggest that active and aggressive multidisciplinary management of ALS patients improve their quality of life and prolong their survival. Patient and caregiver communications and decisions are increasingly recognized to be a relevant part of this management. A wide range of supportive and palliative measures, in particular the widely use of symptomatic drugs for pseudobulbar affect, sialorrhea, and sleep disorders is available to relieve patients symptomatology. In addition, patients quality of life has been profoundly improved by the introduction of enteral nutrition and non-invasive ventilation.


Subject(s)
Motor Neuron Disease/therapy , Palliative Care , Disease Progression , Humans , Motor Neuron Disease/diagnosis , Motor Neuron Disease/psychology , Palliative Care/psychology , Patient Care Team , Quality of Life/psychology , Terminal Care/psychology
12.
Mult Scler ; 12(6): 814-23, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17263012

ABSTRACT

Over the last decade, hematopoietic stem cells transplantation (HSCT) has been increasingly used in the treatment of severe progressive autoimmune diseases. We report a retrospective survey of 183 multiple sclerosis (MS) patients, recorded in the database of the European Blood and Marrow Transplantation Group (EBMT). Transplant data were available from 178 patients who received an autologous graft. Overall, transplant related mortality (TRM) was 5.3% and was restricted to the period 1995-2000, with no further TRM reported since then. Busulphan-based regimens were significantly associated with TRM. Clinical status at the time of transplant and transplant techniques showed some correlations with toxicity. No toxic deaths were reported among the 53 patients treated with the BEAM (carmustine, etoposide, cytosine-arabinoside, melphalan)/antithymocyte globulin (ATG) regimen without graft manipulation, irrespective of their clinical condition at the time of the transplant. Improvement or stabilization of neurological conditions occurred in 63% of patients at a median follow-up of 41.7 months, and was not associated with the intensity of the conditioning regimen. In this large series, HSCT was shown as a promising procedure to slow down progression in a subset of patients affected by severe, progressive MS; the safety and feasibility of the procedure can be significantly improved by appropriate patient selection and choice of transplant regimen.


Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/mortality , Multiple Sclerosis, Chronic Progressive/mortality , Multiple Sclerosis, Chronic Progressive/therapy , Adolescent , Adult , Databases, Factual , Disability Evaluation , Disease Progression , Europe , Female , Follow-Up Studies , Hematopoietic Stem Cell Mobilization/adverse effects , Hematopoietic Stem Cell Mobilization/mortality , Humans , Male , Middle Aged , Multiple Sclerosis, Chronic Progressive/physiopathology , Registries , Retrospective Studies , Survival Analysis , Transplantation, Autologous
13.
J Neurol ; 252(10): 1167-70, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16184341

ABSTRACT

BACKGROUND: Orolingual angioedema can occur during thrombolysis with alteplase in stroke patients. However, data about its frequency, severity and the significance of concurrent use of angiotensin-converting-enzyme inhibitors (ACEi) are sparse. OBJECTIVE: (1), to alert to the potentially life-threatening complication of orolingual angioedema. (2), to present CT-scans of the tongue which exclude lingual hematoma. (3), to estimate the frequency of orolingual angioedema. (4), to evaluate the risk associated with the concurrent use of ACEi. METHODS: Single center, databank-based observational study on 120 consecutive patients with i. v. alteplase for acute stroke. Meta-analysis of all stroke studies on alteplase-associated angioedema, which provided detailed information about the use of ACE-inhibitors. Across studies, the Peto odds ratio of orolingual angioedema for "concurrent use of ACEi" was calculated. RESULTS: Orolingual angioedema occurred in 2 of 120 patients (1.7%, 95% CI 0.2-5.9 %). Angioedema was mild in one, but rapidly progressive in another patient. Impending asphyxia prompted immediate intubation. CT showed orolingual swelling but no bleeding. One of 19 (5%) patients taking ACEi had orolingual angioedema, compared to 1 of 101 (1%) patients without ACEi. Medline search identified one further study about the occurrence of alteplase-associated angioedema in stroke patients stratified to the use of ACEi. Peto odds ratio of 37 (95 % CI 8-171) indicated an increased risk of alteplasetriggered angioedema for patients with ACEi (p <0.001). CONCLUSION: Orolingual angioedema is a potentially life-threatening complication of alteplase treatment in stroke patients, especially in those with ACEi. Orolingual hematoma as differential diagnosis can be excluded by CT-scan.


Subject(s)
Angioedema/etiology , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Stroke/drug therapy , Thrombolytic Therapy/adverse effects , Tissue Plasminogen Activator/adverse effects , Acute Disease , Aged , Aged, 80 and over , Angioedema/chemically induced , Angioedema/epidemiology , Angioedema/pathology , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Brain Ischemia/complications , Confidence Intervals , Drug Synergism , Humans , Incidence , Middle Aged , Mouth/pathology , Odds Ratio , Prospective Studies , Risk Factors , Severity of Illness Index , Stroke/complications , Time Factors , Tissue Plasminogen Activator/therapeutic use , Tomography, X-Ray Computed , Tongue/pathology
14.
J Neurol ; 252(11): 1387-93, 2005 Nov.
Article in English | MEDLINE | ID: mdl-15942704

ABSTRACT

OBJECTIVE: In acute ischemic stroke, the number and distribution of lesions on diffusion weighted imaging (DWI) have been shown to give clues to the underlying pathogenetic mechanisms. The objective of this study was to determine whether lesion features on DWI differ between stroke due to large artery atherosclerosis (LAA) and cardioembolism (CE), and to assess the role of apparent diffusion coefficient maps (ADC). METHODS: We retrospectively studied 83 consecutive patients with stroke caused by either LAA (n=40) or cardioembolism (n=43). DWI lesions were characterized by number, size, distribution (i. e. lesion pattern) and signal intensity on ADC maps. In part A, all hyperintense DWI lesions regardless of their ADC were compared. In part B, only hyperintense DWI lesions with hypointense appearance on ADC maps (i. e. acute lesions) were assessed. RESULTS: Part A: The frequency of multiple hyperintense DWI lesions (LAA: 28/40, CE: 21/43; p< 0.05) and the lesion number (LAA 4.7+/- 4.9; CE: 3.1+/- 4.7; p=0.01) were higher in LAA-patients. Involvement of >1 circulation (i. e. anterior plus posterior or bilateral anterior circulations) was present in 5 LAA-patients (13 %) and 4 CE-patients (9 %). Lesion size did not differ between LAA-stroke (35.1+/- 33.7 mm) and CE-stroke (35.4+/- 27.8 mm). Part B: Multiple hyperintense DWI lesions with low ADC occurred in 23/40 LAA-patients and in 15/43 CE-patients (p<0.05). Lesions in >1 circulation occurred only in CE-stroke (n=3; 7%) and never in LAA-stroke. CONCLUSIONS: (1) Multiple ischemic lesions occur significantly more often in LAA-stroke than in CE-stroke. (2) ADC maps are important in the comparison of DWI lesion patterns; DWI lesions in >1 circulation can only be assigned to a cardioembolic etiology if they appear hypointense on ADC maps.


Subject(s)
Diffusion Magnetic Resonance Imaging , Stroke/diagnostic imaging , Stroke/etiology , Aged , Atherosclerosis/complications , Atherosclerosis/diagnostic imaging , Atherosclerosis/pathology , Embolism/complications , Embolism/diagnostic imaging , Embolism/pathology , Female , Heart Diseases/diagnostic imaging , Humans , Male , Middle Aged , Radiography , Retrospective Studies , Stroke/pathology
17.
Eur J Neurol ; 11(8): 567-8, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15272904

ABSTRACT

We describe a case of a 65-year old patient diagnosed with amyotrophic lateral sclerosis. The clinical findings, with symmetric, predominantly proximal wasting and weakness of both arms (especially of the infra-, supraspinatus and deltoideus) leading to severe functional disability and contrasting with preserved independent ambulation and sparing of bulbar muscles, were consistent with the proposed criteria of the so-called flail arm syndrome. Based on our case we characterize the clinical features of flail arm syndrome and review the literature.


Subject(s)
Amyotrophic Lateral Sclerosis/complications , Arm/physiopathology , Disabled Persons , Aged , Amyotrophic Lateral Sclerosis/classification , Humans , Male
18.
Neurology ; 62(4): 574-80, 2004 Feb 24.
Article in English | MEDLINE | ID: mdl-14981173

ABSTRACT

OBJECTIVE: To study the association between diffusion-weighted imaging (DWI) characteristics and stroke etiology, stroke severity, and functional outcome in patients with infratentorial strokes. METHODS: The authors prospectively studied 22 consecutive patients with acute infratentorial strokes. They used a blinded comparison of DWI features (number, distribution, and volume of lesions) with clinical characteristics, namely, stroke etiology (Trial of ORG 10172 in Acute Stroke Treatment [TOAST] classification), severity (NIH Stroke Scale [NIHSS]), length of stay (LOS), and functional 3-month outcome using modified Rankin Scale, Barthel Index, and a dichotomized outcome status (living at home vs institutionalization or death). RESULTS: Acute infratentorial DWI lesions were detected in 95% (21/22) of the patients. The number (p = 0.01) and the distribution (p < 0.001) of DWI lesions were correlated with stroke etiology. Patients with cardioembolic strokes (n = 5) had more DWI lesions (8.0 +/- 6.0) than those with other stroke etiologies (n = 17; 1.3 +/- 0.9; p < 0.001). Their lesion distribution differed from that of patients with noncardioembolic strokes (p < 0.001). Clinically silent, acute DWI lesions in the anterior circulation in addition to their infratentorial lesions were visualized in 3 of 5 patients with cardioembolic stroke and in none of 17 patients without sources of cardioembolism (p < 0.001). Pure infratentorial lesions were present in 15 of 17 patients with noncardioembolic strokes and in none of 5 cardioembolic stroke patients (p < 0.001). DWI lesion volume was not correlated with NIHSS score, LOS, outcome scores, or outcome status. CONCLUSION: In infratentorial strokes, multiple DWI lesions and a distribution of subsidiary, clinically silent DWI lesions in the anterior circulation suggest a cardioembolic stroke etiology. However, DWI lesion volume did not correlate with the NIHSS score and was no predictor of outcome.


Subject(s)
Magnetic Resonance Imaging/methods , Stroke/pathology , Adult , Aged , Brain Damage, Chronic/epidemiology , Brain Damage, Chronic/etiology , Cerebellum/blood supply , Female , Heart Diseases/complications , Humans , Intracranial Arteriosclerosis/complications , Intracranial Arteriosclerosis/pathology , Intracranial Embolism/etiology , Intracranial Embolism/pathology , Length of Stay , Male , Mesencephalon/blood supply , Middle Aged , Pons/blood supply , Prospective Studies , Risk Factors , Severity of Illness Index , Single-Blind Method , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...